ARO-HSD is the first RNA interfering (RNAi) therapeutic agent that knocks down hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA and protein levels and protects patients with NASH with acceptable tolerability (56). This evidence concerns the gene HSD17B13 and metabolic dysfunction-associated steatohepatitis.